The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Epigenetic control of CD4/CD8 lineage commitment and resistance to tumor infiltrating lymphocyte adoptive cell therapy for metastatic melanoma.
 
David Michael Woods
Stock and Other Ownership Interests - Bristol-Myers Squibb; Lion Biotechnologies
Research Funding - Mirati Therapeutics
 
Anders E. Berglund
Stock and Other Ownership Interests - Pfizer
 
Amod Sarnaik
Stock and Other Ownership Interests - Merck
Research Funding - Genentech; Lion Biotechnologies; Proventus Group
Patents, Royalties, Other Intellectual Property - Lion Biotechnologies
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Celldex; Merck
Honoraria - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Merck; Merck; Pieris Pharmaceuticals; Roche
Consulting or Advisory Role - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Merck; Merck; Pieris Pharmaceuticals; Roche
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Lion Biotechnologies; Merck; Merck; Pieris Pharmaceuticals; Roche